Zicam nasal swabs, Orajel teething swabs recalled nationwide over potential fungal contamination
Check your medicine cabinet — Zicam nasal swabs and Orajel baby teething swabs are being recalled due to potential microbial contamination, according to federal health officials.
In an alert from the U.S. Food and Drug Administration, Church & Dwight Co., Inc., the brands' manufacturer, voluntarily issued the recall after the potential contamination was discovered, which was identified as fungi in the cotton swab components of the products.
The recalled products include all lots of Zicam Cold Remedy Nasal Swabs (with UPC 732216301205), all lots of Zicam Nasal AllClear Swabs (UPC 732216301656) and all lots of Orajel Baby Teething Swabs (UPC 310310400002). All other Zicam and Orajel products are not affected by this recall, the FDA said.
The Zicam and Orajel recall includes Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs and Orajel Baby Teething Swabs, the FDA said.
FDA
Consumers with any recalled products should stop using them immediately, the FDA advised.
Swabs with microbial contamination can present significant health and safety risks, including serious and life-threatening blood infections, the agency added. The highest risk is among children and people with compromised immune systems or other underlying medical conditions.
So far, no serious adverse events have been reported in connection to the recalled products.
For a full refund, visit www.churchdwightrecall.com or call (800) 981-4710.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Hims & Hers, healthcare stocks, BNY: Trending Tickers
Novo Nordisk (NVO) ended its weight-loss drug partnership with Hims & Hers (HIMS), sending shares of both companies lower. UnitedHealth (UNH), CVS (CVS), and Cigna (CI) are in focus as health insurers are set to simplify the authorization process, according to AHIP. BNY (BNY) is reportedly considering a merger with Northern Trust (NTRS), according to the Wall Street Journal. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Hims & Hers stock plummets after Novo Nordisk ends Wegovy direct sales deal
Hims & Hers (HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk (NVO) announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims' telehealth platform. Novo Nordisk said that Hims & Hers was breaking the law by continuing to sell copycat semaglutide, the key ingredient in Wegovy, alongside Novo's branded drugs. "Hims & Hers ... has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization,'" Novo said in a statement Monday. The duo announced a collaboration last month that would allow patients to directly purchase Wegovy through Hims' telehealth platform. The agreement followed a growing trend among pharma companies, including Novo's competitor Eli Lilly (LLY) to fill the access gap after copycat, or compounded, GLP-1s were forced off the market. Compounded drugs were available when Lilly and Novo struggled to produce enough of their GLP-1s to meet the unexpected and unprecedented demand spike in the weight-loss market. The Food and Drug Administration (FDA) allows for copycats to be sold when a drug is in short supply without undergoing the same trial requirements as the branded drugs. Since the shortage has ended for both companies' drugs, some compounding pharmacies have continued to make copycats — mostly for Novo's semaglutide. They intend to continue and are allowed to do so due to a loophole that allows patients to have access to "personalized" medicine if they need adjustments to a branded product for reasons like tolerability or allergies. Lilly is also faced with how to manage some telehealth platforms that continue to offer compounded products, including Novo Nordisk's, which Lilly included in its concerns. Hims & Hers did not immediately respond to a request for comment. In addition to the latest ding to the company's stock, investors are expecting Hims & Hers to grow at a slower clip than in the recent past. Hims has been riding the highs (and sometimes volatile swings) in GLP-1 news, especially as it relates to the availability of the copycat drugs. But it is also showing weakness in overall subscriptions to its telehealth platform, according to Bank of America analyst Allen Lutz. Revenue growth year over year has slowed sharply from roughly 45% in the third quarter of 2024 to 29% in the first quarter of this year. In addition, the Federal Trade Commission (FTC) will implement a new rule in July making it easier for customers to cancel subscriptions with one click, which "could impact HIMS churn by simplifying subscription cancellations," Lutz said. Meanwhile, pressure from Congress and the federal government to end direct-to-consumer marketing for pharmaceutical sales could impact Hims, which faced backlash after it advertised compounded GLP-1s during the Super Bowl in February. But there is one potential bright spot, according to Lutz. Hormone replacement therapy (HRT), a potentially $3 billion to $10 billion market, could add $4 million to $12 million for Hims in 2025. "HIMS has a strong history of scaling new categories quickly and hormone replacement therapy (HRT) is the next opportunity," Lutz wrote. "HIMS' DTC [direct-to-consumer] offering is likely to expand the current addressable market over time given strong brand recognition." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
The best summer AC temperature? Experts have an unpopular answer.
Summer 2025 is here and temperatures are reaching dangerous levels, making air conditioning important for comfort and safety. But what temperature should you set your thermostat at? The answer is a balancing act between energy savings, comfort and safety. 'It is essential to stay cool during hot weather — use air conditioning or go to a cool place where you feel comfortable,' Dr. Michelle Morse, New York City's acting health commissioner, said in a statement. 'Heat is dangerous, but taking certain precautions can prevent illness and protect your health.' People also have bills to pay as AC demand skyrockets. Here are ways to stay cool while balancing budgets. Summer 2025 brings killer heat. Here are some surprising ways to stay safe. The best temperature to set your air conditioning is 78 degrees Fahrenheit when you wake up, according to the U.S. Environmental Protection Agency's Energy Star program. Energy companies in Florida, Maryland and Missouri also recommend thermostats at 78 degrees during summer months. Not many people follow this recommendation, as a 2021 Consumer Reports survey showed. And a 2024 poll from the Detroit Free Press, part of the USA TODAY Network, found 72 degrees was a favorite among readers. But setting your thermostat at a higher temperature can maximize efficiency. As temperatures ideally drop at night, people should set thermostats 4 degrees warmer when they go to sleep. If you're away from home, you can avoid unnecessary energy usage by setting temperatures 7 degrees warmer, the energy department said. Even 7 to 10 degrees, for around 8 hours daily, can save up to 10% annually on cooling and heating. Since windows bring in heat, window curtains can help keep indoors cooler. Look for air leaks — such as windows, baseboards and doors — and seal them to keep cool air in and hot air outside. Reduce use of appliances that generate heat, such as stoves or ovens. Use fans to circulate cool air, but don't use them as your only cooling device. There are other methods to stay cool, which USA TODAY compiled here. You should also check on others who may be more vulnerable to heat-related illness, including young children, older people and people with chronic health issues. If it gets too hot, look for a nearby cooling center. Even public areas, such as malls, museums or pools, can give critical respite. Contributing: Jeanine Santucci and Greta Cross, USA TODAY. Eduardo Cuevas is based in New York City. Reach him by email at emcuevas1@ or on Signal at emcuevas.01. This article originally appeared on USA TODAY: Experts say this is best AC temperature amid heat wave
